Sai Life Sciences (SAILIFE) investor relations material

Executive summary

• FY26 achieved 29% revenue growth, 56% EBITDA growth, and 109% PAT growth, driven by strong CRO and CDMO performance and deepened global pharma relationships, with integrated CRDMO capabilities positioning for long-term innovation-led outsourcing.

• Large pharma client revenue contribution rose to 49% in FY26 from 28% in FY22, reflecting deepening strategic relationships.

• Four new commercial molecules added, totaling 34, with 11 in phase III/pre-registration and 155 in earlier development stages.

• Audited standalone and consolidated financial results for FY26 and Q4FY26 were approved, with unmodified auditor opinions.

• The group operates in a single segment: Contract Research, Development and Manufacturing Services (CRDMO).

Financial highlights

• FY26 consolidated revenue was ₹2,192 Cr (Rs. 21,924.92 million), up 29% year-over-year from ₹1,695 Cr (Rs. 16,945.70 million) in FY25.

• EBITDA rose 56% to ₹661 Cr, with margin expanding by 508 bps to 30% due to operating leverage.

• PAT before exceptional items increased 109% to ₹355 Cr, compared to ₹170 Cr in FY25.

• CDMO revenue grew 33% to ₹1,417 Cr; CRO revenue grew 24% to ₹775 Cr.

• Standalone net profit for FY26 was Rs. 3,414.81 million, up from Rs. 1,734.62 million; consolidated net profit was Rs. 3,489.10 million, up from Rs. 1,701.32 million year-over-year.

Outlook and guidance

• Targeting 15–20% annual revenue growth and maintaining EBITDA margins in the 28–30% range over the next three years.

• Second half of FY27 expected to be stronger due to new capacities coming online.

• CapEx guidance for FY27 is INR 1,100–1,300 crores, with 75% for capacity expansion and 25% for capability and technology, including AI.

• The company will continue to monitor and account for any further clarifications or impacts from the new Labour Codes in future periods.